{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:23:32Z","timestamp":1791296612369,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,10,21]],"date-time":"2014-10-21T00:00:00Z","timestamp":1413849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>We estimated and compared the residual risks due to window\u2010period donations for pooled and apheresis platelets in Germany using a modification of a previously described statistical model. This model directly utilizes the reported interdonation intervals before a positive donation and reflects in this aspect the look\u2010back procedures used in haemovigilance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Data from the German National Blood Donor Surveillance System for the years 2006\u20132012, including reports about donations from repeat donors with confirmed positive test results for <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> HCV<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content>, were used to estimate the risk of undetected infectious units for both pooled and apheresis platelets.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Demographics of whole\u2010blood and apheresis donors differed in age, gender, catchment area and interdonation interval. These differences impact on the prevalence and incidence of transfusion relevant infections and consequently the residual risk. The estimates for the residual risks for pooled and apheresis platelets were comparable. For <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>, there was no significant difference, for <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> apheresis platelets had a lower residual risk, whereas pooled platelets had a lower risk for undetected <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content> infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings do not support calls for a shift to an apheresis platelets\u2010only policy in Germany.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vox.12204","type":"journal-article","created":{"date-parts":[[2014,10,27]],"date-time":"2014-10-27T10:13:18Z","timestamp":1414404798000},"page":"123-130","source":"Crossref","is-referenced-by-count":16,"title":["Estimating the residual risk for <scp>HIV<\/scp>,<scp> HCV<\/scp> and <scp>HBV<\/scp> in different types of platelet concentrates in Germany"],"prefix":"10.1111","volume":"108","author":[{"given":"M.","family":"an der Heiden","sequence":"first","affiliation":[{"name":"Department of Infectious Disease Epidemiology Robert Koch Institute Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ritter","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology Robert Koch Institute Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hamouda","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology Robert Koch Institute Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Offergeld","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology Robert Koch Institute Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,10,21]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"Paul\u2010Ehrlich\u2010Institut:Tabelle zur Meldung nach \u00a7 21 Transfusionsgesetz f\u00fcr das Jahr 2012 http:\/\/www.pei.de\/DE\/infos\/meldepflichtige\/meldung-blutprodukte-21-transfusionsgesetz\/berichte\/berichte-21tfg-node.html#doc3258776bodyText1(last accessed: 02.09.14)"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-008-0546-1"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000269555"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000328949"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-013-1802-6"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2011.05.008"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01295.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2010.01357.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12063"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2013.02.004"},{"key":"e_1_2_6_12_1","first-page":"1","article-title":"Consistency and proportionality in policy decision\u2010making in blood safety: the case for an all\u2010apheresis platelet supply in Germany","volume":"59","author":"Vamvakas EC","year":"2013","journal-title":"Clin Lab"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1213383"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606273342601"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00204.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03940.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03840.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03344.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2012.01584.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/3.1.133"},{"key":"e_1_2_6_21_1","unstructured":"Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Haemotherapie). BAnz 2010; 101a."},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-012-1516-1"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-010-1152-6"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-008-0612-8"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01718.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2807\/esm.10.02.00522-en","article-title":"Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000\u20132002: risk of virus transmission and the impact of nucleic acid amplification testing","volume":"10","author":"Offergeld R","year":"2005","journal-title":"Euro Surveill"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2009.00947.x"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03281.x"},{"key":"e_1_2_6_29_1","first-page":"273","article-title":"Virushepatitis im Jahr 2012","volume":"30","author":"RKI","year":"2012","journal-title":"Epid Bull"},{"key":"e_1_2_6_30_1","first-page":"214","article-title":"HIV\u2010Infektionen und AIDS\u2010Erkrankungen in Deutschland","volume":"26","author":"RKI","year":"2014","journal-title":"Epid Bull"},{"key":"e_1_2_6_31_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7754\/Clin.Lab.2014.140210","article-title":"Single\u2010donor (apheresis) platelets and pooled whole blood derived platelets \u2010 significance and assessment of both blood products","volume":"60","author":"Hitzler WE","year":"2014","journal-title":"Clin Lab"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.04215.x"},{"key":"e_1_2_6_33_1","first-page":"940","article-title":"\u201cBlood\u201d (Arbeitskreis Blut) of the German federal Ministry of Health: lookback procedure","volume":"49","author":"Announcement of the National Advisory Committee","year":"2006","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-012-1515-2"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00099.x"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-393637"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12299"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000117788"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fvox.12204","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.12204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T10:57:31Z","timestamp":1696157851000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.12204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,21]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1111\/vox.12204"],"URL":"https:\/\/doi.org\/10.1111\/vox.12204","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,21]]}}}